# A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer

> **NCT00697060** · PHASE2 · WITHDRAWN · sponsor: **AmpliMed Corporation**

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Imexon + docetaxel

## Key facts

- **NCT ID:** NCT00697060
- **Lead sponsor:** AmpliMed Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-08
- **Primary completion:** 2011-08
- **Final completion:** 2012-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study cancelled prior to start due to change in company priorities.
- **Last updated:** 2015-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00697060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00697060, "A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00697060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*